Dr Reddy's launches OTC olopatadine hydrochloride ophthalmic solution in US
This story was originally published at 19:31 IST on 14 January 2026
Register to read our real-time news.Informist, Wednesday, Jan. 14, 2026
--Dr Reddy's, arms launch olopatadine hydrochloride ophthalmic solution in US
HYDERABAD - Dr. Reddy's Laboratories Ltd. Thursday announced the launch of over-the-counter olopatadine hydrochloride ophthalmic solution with 0.7% strength in the US, following approval from the US Food and Drug Administration.
The product is the generic equivalent of Extra Strength Pataday and is indicated for temporary relief of itchy eyes caused by allergens such as pollen, grass, and animal dander. The solution is available in 2.5-millilitre bottles.
The launch expands Dr. Reddy's over-the-counter eye-care portfolio, which already includes olopatadine hydrochloride ophthalmic solution in 0.1% and 0.2% strengths, and marks a first-to-market store-brand offering. The Pataday brand, owned by Novartis AG, recorded US sales of about $69.9 million over the latest 52-week period ended Dec. 27, according to data from global marketing research firm NIQ.
Wednesday, Dr. Reddy's shares ended at INR 1,186.50 on the National Stock Exchange, down 0.4%. End
US$1 = INR 90.29
Reported by Narayana Krishna
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
